拿地金额排名第四，土地质量提升显著 根据克而瑞数据，公司1-5 月拿地金额331.6 亿元，同比+53%，排名行业第四；新增土地货值650.3 亿 元，新增土地建面105.7 亿元，拿地均价31381 元/平，拿地均价超过销售均价，主要由于拿地主要位于 北京、上海、杭州、宁波等高能级城市，土地质量提升显著；拿地强度38.2%，保持较高水平。 经常性收入稳健增长，退出低效资产聚焦核心资产2025 年5 月，公司经常性收入40.9 亿元，同比 +6.2%；其中经营性不动产业务租金收入26.9 亿元，同比+13.0%。1-5 月公司累计经常性收入204.4 亿 元，同比+9.6%；累计经营性不动产业务租金收入132.8 亿元，同比+12.9%。公司旗下位于上海市嘉定 销售维持行业前三，不动产租金收入稳健增长，维持"买入"评级华润置地发布2025 年5 月经营数据，公 司销售维持行业前三，拿地强度较高，经常性收入稳健增长。我们维持盈利预测，预计公司2025-2027 年归母净利润为289.9、317.0、349.1 亿元，对应EPS 为4.07、4.45、4.90 元，当前股价对应PE为6.1、 5.6、5.1 倍， ...

资料图。 在她离开长城汽车加入小鹏汽车任总裁两年多里，对产品规划和定义上的许多举措已初见成效： 截至目前小鹏已经陆续发布了 G6 、 X9 、 M03 （含 Max 版） 和 P7+ 四款全新车型，今 年 1 月，小鹏以月交付新车 30350 辆成为国产新势力第一； 5 月 28 日小鹏汽车发布 MONA M03 Max 版 上市，首周订单达到了 10038 辆。 在与小鹏汽车 CEO 何小鹏先生共进差不多 700 顿午餐后，总裁王凤英女士让小鹏汽车支棱起来 了。 王凤英今年 55 岁。她 在 广州小鹏汽车总部的办公室只有 10 平米， 跟 CEO 何小鹏的相邻。办公 室布置简单，一沙发、一桌两椅。 桌上 除电脑屏幕，无其他个人物品。王凤英每周工作七天，几 乎全年无休。平时不逛街，不购物，不喝酒，最大的快乐是在家自己做衣服。因为不需要再像在长 城时，过着分裂而拉扯的职场生活，她的血压应该也下降了。 01. 王凤英治下，小鹏汽车初见成效 王凤英让小鹏汽车支棱起来了 徐爱之 总裁王凤英在媒体前始终保持着低调。她参加供应商大会、主持招待女性车主的晚宴，在离广州总 部不远的湘菜馆和部门庆功。但不接受媒体采访，小鹏汽车 ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 共聚焦显微镜在荧光显微镜成像基础上加装了激光扫描装置，利用计算机进行图像处理，把光学成像的分辨率提高了 30%以上，从而得到细胞或组织内部微细结构的荧光图像；通过控制Z轴焦平面，还可实现三维成像。如今，共聚焦显 微镜已成为细胞生物学、发育生物学、神经科学、组织成像、类器官和模式生物等领域中新一代强有力的研究工具。 为帮助广大实验室用户及时了解共聚焦显微成像创新技术及前沿进展，仪器信息网将于 2025年6月18日 举办 "第二 届共聚焦显微成像技术及应用进展" 主题网络研讨会，围绕 共聚焦显微成像新技术新方法 、以及在 细胞生物学 、 神经科学 和 疾病研究 等领域的应用进展进行探讨交流，为科研工作者和相关从业人员搭建一个即时、高效的交流和 学习的平台。 亮点前瞻： 技术前沿： 囊括 共聚焦成像与人工智能融合、快速超分辨显微成像、受激拉曼散射成像、超多标记成像、透明化包埋 技术、原子力显微镜与共聚焦显微镜联用技术 等 主题方向： 涵盖 共聚焦技术原理讲解、实验技巧分享与平台管理实践 ，以及在 细 ...

Core Viewpoint - Hubei Yihua is intensifying its strategic layout by focusing on its core business and pursuing green transformation through a series of asset disposals and mergers aimed at optimizing resource allocation and enhancing operational efficiency [1][3][5]. Group 1: Strategic Actions - Hubei Yihua's subsidiary, Inner Mongolia Yihua, plans to transfer a 1.718% stake in Lianhai Coal Industry for a base price of 222 million yuan, which will allow the company to concentrate on its main business [2][3]. - The company intends to sell old machinery and equipment from its old factory for 240 million yuan as part of its commitment to the "Yangtze River Protection" policy [1][7]. - Hubei Yihua is merging its wholly-owned subsidiary, New Yihua Chemical, to optimize its management structure and reduce operational costs [1][6]. Group 2: Financial Goals and Performance - Hubei Yihua aims to achieve a revenue of no less than 18 billion yuan by 2025, focusing on enhancing profitability and driving high-quality development [1][5]. - In 2024, the company reported revenues of 16.964 billion yuan and a net profit of 653 million yuan, indicating a robust growth trajectory in its core business [5][6]. Group 3: Industry Context and Future Outlook - The coal chemical sector is a significant part of Hubei Yihua's chemical industry chain, and the company is expanding its coal mining operations to ensure a stable supply of raw materials for its chemical production [4][6]. - The completion of the acquisition of Yinchuan New Development Investment Co. has increased Hubei Yihua's stake in Xinjiang Yihua to 75%, enhancing its competitive position in the market [4][6].

Transaction Overview - The company plans to transfer 48.4213% equity of its subsidiary, Hunan Zhong'an Biological Pharmaceutical Co., Ltd. (Zhong'an Bio), to Jiangxi Twin Biological Technology Co., Ltd. for a transaction price of approximately 11.48 million yuan, based on a total equity value of 23.7 million yuan [1][2][16] - After the transaction, the company will hold 20% of Zhong'an Bio's equity, which will no longer be included in the company's consolidated financial statements [2][24] Fundraising Project Progress - The company raised approximately 1.34 billion yuan through a private placement of 63,984,674 shares at a price of 20.88 yuan per share, with a net amount of approximately 1.33 billion yuan after deducting issuance costs [2][3] - The funds raised are allocated to various projects, including the Zhong'an Bio expansion project, which has reached a usable state and has been completed [5][6] Financial Performance of Zhong'an Bio - As of December 31, 2024, Zhong'an Bio reported a net asset value of approximately 20.55 million yuan, with total assets of approximately 31.77 million yuan and total liabilities of approximately 11.22 million yuan [14][16] - The company experienced a net loss of approximately 45.96 thousand yuan in 2024, compared to a net profit of approximately 10.08 million yuan in 2023 [15][16] Strategic Cooperation - The transaction establishes a strategic partnership between the company and Jiangxi Twin Biological, focusing on vaccine and drug research, product procurement, and disease prevention in the livestock industry [20][24] - Both parties aim to enhance their capabilities in disease prevention and control, leveraging shared resources and expertise [21][22] Board and Supervisory Opinions - The company's board and supervisory committee have approved the equity transfer and fundraising project transfer, stating that it aligns with the company's long-term development strategy and does not harm the interests of shareholders [25][26]

Core Viewpoint - The company, Maike Biological, has decided to transfer its 51% stake in its subsidiary Shandong Maike Biological Technology Co., Ltd. for a transaction price of 17.41 million yuan, aiming to focus on core business and optimize resource allocation [1][3]. Financial Performance - In 2023, Shandong Maike reported revenues of approximately 243 million yuan and a net loss of about 11.04 million yuan. For 2024, revenues are projected to be around 227 million yuan with a net loss of approximately 1.91 million yuan [3]. - Maike Biological's revenue has declined over the years, with figures of 39.81 billion yuan in 2021, 36.08 billion yuan in 2022, 28.96 billion yuan in 2023, and 25.49 billion yuan in 2024. Corresponding net profits were 9.57 billion yuan, 7.08 billion yuan, 3.13 billion yuan, and 1.27 billion yuan respectively [4]. Strategic Decisions - The company aims to enhance market competitiveness and operational quality by divesting from loss-making assets, which is expected to alleviate operational pressure and facilitate capital recovery [3][4]. - Following the transfer, Maike Biological will establish an office in Shandong to manage and expand its dealer network in the region, ensuring that the core business operations remain unaffected [3]. Project Updates - The Maike Biological Tianfu International Biological City IVD Industrial Park project has experienced delays, with the expected operational status now pushed from June to December due to the need for extensive testing and certification of specialized equipment [5].

Group 1 - High temperatures in closed car spaces can exceed 80℃, leading to potential explosions and fires from common items like lighters, perfumes, and power banks [1][5] - A simulation by firefighters showed that lighters can explode within 2 minutes at high temperatures due to the expansion of liquid butane [4][5] - Perfume bottles can eject their nozzles after 20 minutes in high heat, as alcohol inside vaporizes and increases pressure [4][6] Group 2 - Items like sunscreen and aerosol sprays can also explode in high temperatures due to increased internal pressure [6] - A magnifying glass can ignite paper within 40 minutes by focusing sunlight, similar to how other round objects can act as lenses [8] - Power banks can reach temperatures of 137℃ after 50 minutes in a hot car, posing risks of swelling and potential fires, especially if they contain substandard batteries [11] Group 3 - Cooling sprays can cause explosive reactions if used improperly near open flames, as demonstrated in a test where a fire ignited after spraying the product in a closed car [13] - Firefighters advise against leaving items like lighters, perfumes, and power banks in cars during summer to prevent accidents [13]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688136 证券简称：科兴制药 公告编号：2025-034 科兴生物制药股份有限公司 第二届监事会第二十一次会议决议公告 表决结果：3票同意，0票反对，0票弃权。 特此公告。 科兴生物制药股份有限公司监事会 2025年6月11日 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 二、监事会会议审议情况 科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第二十一次会议于2025年6月9日以现场的 方式召开。会议通知已于2025年6月6日发出。本次会议应出席监事3人，实际出席监事3人。 （一）审议通过《关于转让全资子公司股权的议案》 会议由监事会主席江海燕主持。会议召开符合有关法律、法规、规章和《公司章程》的规定。 公司监事会认为：考虑到公司全资子公司深圳同安医药有限公司（以下简称"同安医药"）近年来未实际 开展业务，将公司持有的同安医药100%的股权作价1,500万元转让给广西壮族自治区药物研究所有限公 司（以下简称"广西药研所"），有 ...

Core Viewpoint - The company plans to publicly transfer 90.3085% of its subsidiary Shanghai Qinnian Urban Planning Engineering Design Co., Ltd. through the Ningbo Property Exchange to focus on its main business and enhance core competitiveness [1][2][5]. Transaction Overview - The initial listing price for the shares will not be less than the asset appraisal value, with a minimum price set at RMB 521,600 [2]. - The transaction does not constitute a major asset restructuring as defined by relevant regulations, and does not require approval from authorities [2][5]. Basic Information of the Transaction Target - Shanghai Qinnian was established on January 18, 2006, with a registered capital of RMB 100 million, and operates in various engineering and planning sectors [2]. - The company holds 90,308,500 shares of Shanghai Qinnian, representing 90.3085% of its total equity [2]. Financial Performance of the Target Company - As of the latest audited report, Shanghai Qinnian has total assets of approximately RMB 730.20 million and total liabilities of approximately RMB 746.12 million, resulting in a net asset value of approximately -RMB 15.92 million [3]. - The company reported a revenue of approximately RMB 217.67 million and a net loss of approximately RMB 81.63 million [3]. Valuation and Appraisal - The appraisal report indicates that the total equity value of Shanghai Qinnian is RMB 521,600, reflecting an increase of RMB 16.44 million, with a growth rate of 103.28% [3]. Transaction Process and Authorization - The company’s board has proposed to authorize management to handle all matters related to the public transfer, including adjusting the transfer price and signing agreements with the eventual buyer [4][5]. - The authorization will remain effective until the completion of the transaction [5]. Impact on the Company - The transfer of shares is aimed at concentrating resources on core business areas, thereby improving the company's strategic development and long-term interests [5][6]. - Following the completion of the transaction, Shanghai Qinnian will no longer be included in the company's consolidated financial statements [6]. Independent Director's Opinion - The independent directors support the public transfer of shares, stating it will help the company focus on its main business and optimize its asset structure without harming the interests of shareholders, especially minority shareholders [6].

Group 1 - The independent directors of Zhejiang Provincial Weihai Construction Group Co., Ltd. held a special meeting on June 10, 2025, to review the transfer of equity in a controlling subsidiary through public listing [1] - The review concluded that the public transfer of equity in Shanghai Qinnian is beneficial for the company to focus on its main business, optimize its industrial structure, and improve asset utilization efficiency [1] - The independent directors agreed that the equity transfer does not harm the interests of the company and its shareholders, especially minority shareholders, and consented to submit the matter for shareholder meeting approval [1]